Oak Ridge Investments LLC Reduces Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Oak Ridge Investments LLC decreased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 30.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,342 shares of the company’s stock after selling 37,464 shares during the period. Oak Ridge Investments LLC’s holdings in Hims & Hers Health were worth $2,088,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Commonwealth Equity Services LLC bought a new position in Hims & Hers Health during the 2nd quarter valued at about $479,000. Victory Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares during the period. State of New Jersey Common Pension Fund D bought a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $1,918,000. DekaBank Deutsche Girozentrale purchased a new position in Hims & Hers Health during the 2nd quarter valued at $143,000. Finally, Mercer Global Advisors Inc. ADV grew its position in Hims & Hers Health by 1,391.3% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 149,176 shares of the company’s stock valued at $3,012,000 after acquiring an additional 139,173 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of recent analyst reports. TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Piper Sandler lifted their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. Needham & Company LLC increased their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Finally, Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $25.13.

Insider Activity at Hims & Hers Health

In related news, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the sale, the insider now owns 193,980 shares in the company, valued at $4,306,356. This represents a 3.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the transaction, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. This trade represents a 73.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,080,208 shares of company stock valued at $29,106,823 in the last three months. 17.71% of the stock is owned by insiders.

Hims & Hers Health Trading Down 0.5 %

NYSE HIMS opened at $27.80 on Friday. Hims & Hers Health, Inc. has a 12-month low of $8.14 and a 12-month high of $35.02. The firm’s fifty day simple moving average is $27.68 and its two-hundred day simple moving average is $21.85. The firm has a market capitalization of $6.07 billion, a P/E ratio of 63.19 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.04) EPS. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.